NCT04909892

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

A Phase 2a Study of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sorrento Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1b study to assess the safety and efficacy of COVI-MSC in treating post COVID-19 "long haulers" with pulmonary compromise.

Detailed description

This is a Phase 1b multicenter study to assess the safety and efficacy of COVI-MSC in treating post COVID-19 "long haulers" with pulmonary compromise. COVI-MSC will be administered intravenously on Day 0, Day 2, and Day 4.

Conditions

• Covid19

Interventions

Type	Name	Description
BIOLOGICAL	COVI-MSC	COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells

Timeline

• Start date: 2021-08-01
• Primary completion: 2022-01-01
• Completion: 2022-01-01
• First posted: 2021-06-02
• Last updated: 2021-09-16

Regulatory

• FDA-regulated drug study